Cyclodextrins in ocular drug delivery: Theoretical basis with dexamethasone as a sample drug

Journal of Drug Delivery Science and Technology

Volumn 17, Issue 1, 2007, Pages 3-9

  Loftsson, T ^a   Stefansson E ^b  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Aqueous solution; Availability; Cyclodextrin; Dexamethasone; Eye drops; Ophthalmic; Permeation; Topical drug delivery

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACETAZOLAMIDE; ALPHA CYCLODEXTRIN; ANANDAMIDE; BETA CYCLODEXTRIN; CANNABINOID DERIVATIVE; CHLORAMPHENICOL; CLOROCIL; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN; DEXAMETHASONE; DICLOFENAC; DIPIVEFRINE; DISULFIRAM; DORZOLAMIDE; EYE DROPS; FLUOROMETHOLONE; GAMMA CYCLODEXTRIN; GANCICLOVIR DERIVATIVE; HYDROCORTISONE; LOTEPREDNOL ETABONATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PILOCARPINE; PRASTERONE; PROSTAGLANDIN DERIVATIVE; RUFLOXACIN; THALIDOMIDE; TROPICAMIDE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AQUEOUS SOLUTION; COMPLEX FORMATION; DIFFUSION COEFFICIENT; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; EYE; HUMAN; HYDROPHILICITY; LIPOPHILICITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; TEAR FILM;

EID: 33847411896     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(07)50001-8     Document Type: Review

References (86)

1. Ahmed I., Gokhale R.D., Shah M.V., Patton T.F. - Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. - J. Pharm. Sci., 76, 583-586, 1987.
2. Wang W., Sasaki H., Chien D.-S., Lee V.H.L. - Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. - Curr. Eye Res., 10, 571-579, 1991.
3. Loftsson T., Stefánsson E. - Effect of cyclodextrins on topical drug delivery to the eye. - Drug Devel. Ind. Pharm., 23, 473-481, 1997.
4. Chrai S.S., Patton T.F., Mehta A., Robinson J.R. - Lacrimal and instilled fluid dynamics in rabbit eye. - J. Pharm. Sci., 62, 1112-1121, 1973.
5. Urtti A., Salminen L. - Minimizing systemic absorption of topically administered ophthalmic drugs. - Surv. Ophthalmol., 37, 435-456, 1993.
6. Loftsson T., Järvinen T. - Cyclodextrins in ophthalmic drug delivery. - Adv. Drug Deliv. Rev., 36, 59-79, 1999.
7. Duchêne D. (Ed.) - Cyclodextrins and their Industrial Uses. - Editions de Santé, Paris, 1987.
8. Szejtli J. - Cyclodextrin Technology. - Kluwer Academic Publisher, Dordrecht, 1988.
9. Duchêne D. (Ed.) - New Trends in Cyclodextrins and Derivatives. - Editions de Santé, Paris, 1991.
10. Frömming K.H., Szejtli J. - Cyclodextrins in Pharmacy. - Kluwer Academic Publishers, Dordrecht, 1994.
11. Loftsson T., Brewster M.E. - Pharmaceutical applications of cyclodextrins. 1.Drug solubilization and stabilization. - J. Pharm. Sci., 85, 1017-1025, 1996.
12. Rajewski R.A., Stella V.J. - Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. - J. Pharm. Sci., 85, 1142-1168, 1996.
13. Irie T., Uekama K. - Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. - J. Pharm. Sci., 86, 147-162, 1997.
14. Stella V. J., Rajewski R. A. - Cyclodextrins: their future in drug formulation and delivery. - Pharm. Res., 14, 556-567, 1997.
15. Thompson D.O. - Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. - Crit. Rev. Ther. Drug Carrier Syst., 14, 1-104, 1997.
16. Uekama K. - Cyclodextrins in drug delivery. - Advanced Drug Delivery Reviews, 36 (1), 1999.
17. D'souza V.T., Lipkowitz K.B. - Cyclodextrins. - Chem. Rev., 98 (5), 1998.
18. Loftsson T., Stefánsson E. - Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. - Acta Ophthalmol. Scand., 80, 144-150, 2002.
19. Kaur I.P., Chhabra S., Aggarwal D. - Role of cyclodextrins in ophthalmics. - Curr. Drug Deliv., 1, 351-360, 2004.
20. Loftsson T., Brewster M.E., Másson M. - Role of cyclodextrins in improving oral drug delivery. - Am. J. Drug Deliv., 2, 261-275, 2004.
21. Del Valle E.M.M. - Cyclodextrins and their uses: a review. - Process Biochem., 39, 1033-1046, 2004.
22. Loftsson T., Jarho P., Másson M., Järvinen T. - Cyclodextrins in drug delivery. - Expert Opin. Drug Deliv., 2, 335-351, 2005.
23. Loftsson T., Másson M. - The effects of water-soluble polymers on cyclodextrins and cyclodextrin solubilization of drugs. - J. Drug Del. Sci. Tech., 14, 35-43, 2004.
24. Loftsson T., Másson M., Brewster M. E. - Self-association of cyclodextrins and cyclodextrin complexes. - J. Pharm. Sci., 93, 1091-1099, 2004.
25. Pitha J., Milecki J., Fales H., Pannell L., Uekama K. - Hydroxypropyl-β-cyclodextrin: preparation and characterization; effects on solubility of drugs. - Int. J. Pharm., 29, 73-82, 1986.
26. Loftsson T., Matthíasson K., Másson M. - The effects of organic salts on the cyclodextrin solubilization of drugs. - Int. J. Pharm., 262, 101-107, 2003.
27. Loftsson T., Brewster M. E., Derendorf H., Bodor N. - 2-hydroxypropyl-β-cyclodextrin: properties and usage in pharmaceutical formulations. - Pharm. Ztg. Wiss., 136, 5-10, 1991.
28. Loftsson T., Konrádsdóttir F., Másson M. - Influence of aqueous diffusion layer on passive drug diffusion from aqueous cyclodextrin solutions through biological membranes. - Pharmazie, 61, 83-89, 2006.
29. Flynn G.L., Carpender O.S., Yalkowsky S.H. - Total mathematical resolution of diffusion layer control of barrier flux. - J. Pharm. Sci., 61, 312-314, 1972.
30. Loftsson T., Masson M. - Cyclodextrins in topical drug formulations: theory and practice. - Int. J. Pharm., 225, 15-30, 2001.
31. Masson M., Loftsson T., Masson G., Stefansson E. - Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. - J. Control. Rel., 59, 107-118, 1999.
32. Florence A.T., Attwood D. - Physicochemical Principles of Pharmacy. - Fourth ed., Pharmaceutical Press, London, 2006.
33. Moldenhauer J. - Personal communication: octanol/water partition coefficients of cyclodextrins. - Wacker-Chemie GmbH, Burghausen, 2004.
34. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. - A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm. Res., 12, 413-420, 1995.
35. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. - Experimental and computatorial approaches to estimate solubility and permeability in drug discovery and development settings. - Adv. Drug Deliv. Rev., 46, 3-26, 2001.
36. Sinha V.R., Bindra S., Kumria R., Nanda A. - Cyclodextrin as skin-penetration enhancers. - Pharm. Technol., 27(3), 120-138, 2003.
37. Loftsson T., Sigfússon S. D., Sigurosson H.H., Másson M. - The effects of cyclodextrins on topical delivery of hydrocortisone: the aqueous diffusion layer. - STP Pharma Sci., 13, 125-131, 2003.
38. Merkus F.W.H.M., Verhoef J.C., Marttin E., Romeijn S.G., Van Der Kuy P.H.M., Hermens W.A.J.J., Schipper N.G.M. - Cyclodextrin in nasal drug delivery. - Adv. Drug Deliv. Rev., 36, 41-57, 1999.
39. Yang T., Hussain A., Paulson J., Abbruscato T.J., Ahsan F. - Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. - Pharm. Res., 21, 1127-1136, 2004.
40. Loftsson T., Stefansdottir Ó., Fridriksdottir H., Gudmundsson Ö. - Interaction between preservatives and 2-hydroxypropyl-β- cyclodextrin. - Drug Dev. Ind. Pharm., 18, 1477-1484, 1992.
41. Loftsson T., Hreinsdóttir D., Másson M. - Evaluation of cyclodextrin solubilization of drugs. - Int. J. Pharm., 302, 18-28, 2005.
42. Másson M., Sigurdardóttir B.V., Matthíasson K., Loftsson T. - Investigation of drug-cyclodextrin complexes by a phase-distribution method: some theoretical and practical considerations. - Chem. Pharm. Bull., 53, 958-964, 2005.
43. Loftsson T., Fridriksdottir H., Thorisdottir S., Stefansson E. - The effect of hydroxypropyl methylcellulose on release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations. - Int. J. Pharm., 104, 181-184, 1994.
44. Marttin E., Verhoef J.C., Merkus F.W.H.M. - Efficiency, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. - J. Drug Target., 6, 17-36, 1998.
45. Kristinsson U.K., Frioriksdóttir H., Thórisdóttir S., Siguroardóttir A.M., Stefánsson E., Loftsson T. - Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. - Invest. Ophthalmol. Vis. Sci., 37, 1199-1203, 1996.
46. Saari K.M., Nelimarkka L., Ahola V., Loftsson T., Stefánsson E. - Comparison of 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postoperative inflammation. - Graefe's Arch. Clin. Exp. Ophthalmol., 244, 620-626, 2006.
47. th International Cyclodextrin Symposium, May 21-24, 2000, Ann Arbor, Wacker Biochem Corporation.
48. Loftsson T., Frioriksdóttir H., Thórisdóttir S., Stefánsson E., Siguroardóttir A.M., Guomundsson Ö., Sigthórsson T. - 2-Hydroxypropyl-β-cyclodextrin in topical carbonic anhydrase inhibitor formations.- Eur. J. Pharm. Sci., 1, 175-180, 1994.
49. Loftsson T., Frioriksdóttir H., Stefánsson E., Thórisdóttir S., Guomundsson Ö., Sigthórsson T. - Topically effective ocular hypertensive acetazolamide and ethoxyzolamide formulations in rabbits. - J. Pharm. Pharmacol., 46, 503-504, 1994.
50. Loftsson T., Stefánsson E., Kristinsson J. K., Frioriksdóttir H., Sverrisson T., Guomundsdóttir G., Thórisdóttir S. - Topically effective acetazolamide eye-drop solution in man. - Pharm. Sci., 2, 277-279, 1996.
51. Jarho P., Urtti A., Pate D.W., Suhonen P., JärvinenT. - Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin. - Int. J. Pharm., 137, 209-217, 1996.
52. Pate D.W., Järvinen K., Urtti A., Jarho P., Mette F., Mahadevan V., Järvinen T. - Effects of topical anandamides on intraocular pressure in normotensive rabbits. - Life Sci., 58, 1849-1860, 1996.
53. Laine K., Järvinen T., Savinainen J., Laitinen J.T., Pate D.W., Järvinen K. - Effects of topical anandamide-transport inhibitors, AM404 and olvanil, on ocular pressure in normotensive rabbits. - Pharm. Res., 18, 494-499, 2001.
54. Pate D.W., Järvinen K., Urtti A., Mahadevan V., Järvinen T. - Effect of the CB 1 receptor antagonist, SR 141716A, on cannabinoid-induced ocular hypertension in normotensive rabbits. - Life Sci., 63, 2181-2188, 1998.
55. Laine K., Järvinen K., Mechoulam R., Breuer A., Järvinen T. - Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. - Invest. Ophthalmol. Vis. Sci., 43, 3216-3222, 2002.
56. Laine K., Järvinen K., Pate D. W., Urtti A., Järvinen T. - Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. - Invest. Ophthalmol. Vis. Sci., 43, 393-397, 2002.
57. Kanai A., Alba R.M., Takano T., Kobayashi C., Nakajima A., Kurihara K., Yokoyama T., Fukami M. - The effect on the cornea of alpha cyclodextrin vehicle for cyclosporin eye drops. - Transplant Proc., book1, 21, 3150-3152, 1989.
58. Sasamoto Y., Hirose S., Ohno S., Oneé K., Matsuda H. - Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis. - Ophthalmologica, 203, 118-125, 1991.
59. Cheeks L., Kaswan R. L., Green K. - Influence of vehicle and anterior chamber protein concentration on cyclosporin penetration through the isolated rabbit cornea. - Curr. Eye Res., 11, 641-649, 1992.
60. Kearse E.C., Mcintyre O.L., Johnson M.H., Phillips C.I., Lathe R., Adams W., Green K. - Influence of dehydroepiandrosterone on rabbit intraocular pressure. - Ophthalmic Res., 33, 42-47, 2001.
61. Usayapant A., Karara A. H., Narurkar M.M. - Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. - Pharm. Res., 12, 1495-1499, 1991.
62. Gavrilin M.V., Kompantseva E.V., Gusova B.A., Ushakova L.S., Makarova V.A., Karpenya L.I. - Dexamethasone eye drops based on the products of its interaction with 2-hydroxypropyl-β-cyclodextrin: synthesis and study. - Pharm. Chem. J., 33, 160-163, 1999.
63. Reer O., Bock T.K., Müller B.W. - In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to commercial product Voltaren ophtha. - J. Pharm. Sci., 83, 1345-1349, 1994.
64. Jarho P., Järvinen K., Urtti A., Stella V.J., Järvinen T. - The use of cyclodextrins in ophthalmic formulations of dipivefrin. - Int. J. Pharm., 153, 225-233, 1997.
65. Wang S.L., Di D.X., Ito Y., Nabekura T., Wang S.J., Zhang J.H., Wu C.F. - Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats. - Curr. Eye Res., 29, 51-58, 2004.
66. Sigurosson H. H., Stefánsson E., Guomundsdóttir E., Eysteinsson T., Thorsteinsdóttir M., Loftsson T. - Cyclodextrin formulation of dorzolamide and its distribution in the eye after topical administration. - J. Control. Rel., 102, 255-262, 2005.
67. Tirucherai G.S., Mitra A.K. - Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. - AAPS PharmSciTech, 4(3), Article 45 (www.pharmscitech.org), 2003.
68. rd Int. Symp. Contr. Release Bioact. Mater., Kyoto, 1996.
69. Davies N.M., Wang G., Tucker I.G. - Evaluation of a hydrocortisone/ hydroxypropyl-β-cyclodextrin solution for ocular drug delivery. - Int. J. Pharm., 156, 201-209, 1997.
70. Bary A.R., Tucker I.G., Davies N.M. - Considerations in the use of hydroxypropyl-b-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. - Eur. J. Pharm. Biopharm., 50, 237-244, 2000.
71. Reddy I.K., Khan M.A., Wu W.M., Bodor N.S. - Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. - J. Ocul. Pharmacol. Ther., 12, 159-167, 1996.
72. Knapp S., Bertelmann E., Hartmenn C., Keipert S., Pleyer U. - Intraocular availability of topically applied mycophenolate mofetil in rabbits. - J. Ocul. Pharmacol. Ther., 19, 181-192, 2003.
73. Siefert B., Keipert S. - Influence of α-cyclodextrin and hydroxy-alkylated β-cyclodextrin derivatives on the in vitro corneal uptake and permeation of aqueous pilocarpine-HCI solutions. - J. Pharm. Sci., 86, 716-720, 1997.
74. Freedman K.A., Klein J.W., Crosson C.E. - Beta-cyclodextrins enhance bioavailability of pilocarpine. - Curr. Eye Res., 12, 641, 1993.
75. Keipert S., Fedder J., Böhm A., Hanke B. - Interactions between cyclodextrins and pilocarpine - as an example of a hydrophilic drug. - Int. J. Pharm., 142, 153-162, 1996.
76. Järvinen K., Järvinen T., Thompson D.O., Stella V. - The effect of modified b-cyclodextrin, SBE4-b-CD, on the aqueous solubility and ocular absorption of pilocarpine. - Curr Eye Res., 13, 891-905, 1994.
77. Wheeler L.A. - The use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension. - Eur. Pat. No. O 435 682 A3, 1991.
78. Cappello B., Iervolino M., Miro A., Chetoni P., Burgalassi S., Saettone M.F. - Formulation and preliminary in vivo testing of rufloxacin-cyclodextrin ophthalmic solutions. - J. Incl. Phenom. Macroc. Chem., 44, 173-176, 2002.
79. Siefert B., Pleyer U., Müller M., Hartmann C., Keipert S. - Influence of cyclodextrins on the in vitro permeability and in vivo ocular distribution of thalidomide. - J. Ocular Pharmacol. Therap., 15, 429-438, 1999.
80. Cappello B., Carmignani C., Iervolino M., Rotonda M.I.L., Saettone M.F. - Solubilization of tropicamide by hydroxypropyl-β-cyclodextrin and water-soluble polymers: in vitro/in vivo studies. - Int. J. Pharm., 213, 75-81, 2001.
81. Green K., Kearse E.C. - Ocular penetration of topical D 9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. - Curr. Eye Res., 21, 566-570, 2000.
82. Kearse E.C., Green K. - Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of D9-tetrahydrocannabi-nol. - Curr. Eye Res., 20, 496-501, 2000.
83. th ed., Appelton & Lange, Stamford, 1999.
84. Rowe R.C., Sheskey P.J., Weller P.J. (Eds.) - Handbook of Pharmaceutical Excipients. - Pharmaceutical Press, London, 2003.
85. rd ed., Vol. 2, Pharmaceutical Press, London, 2004.
86. Loftsson T., Sigurdsson H.H., Hreinsdóttir D., Konrádsdóttir F., Stefánsson E. - Dexamethasone delivery to posterior segment of the eye. - J. Incl. Phenom. Macroc. Chem., in print, 2007.